{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:03:36Z","timestamp":1787987016088,"version":"build-2784847793"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T00:00:00Z","timestamp":1763251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T00:00:00Z","timestamp":1763251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007195","name":"Universit\u00e0 degli Studi di Napoli Federico II","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007195","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-025-03206-y","type":"journal-article","created":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T19:42:14Z","timestamp":1763322134000},"page":"551-563","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sex differences among elderly ACS patients undergoing percutaneous coronary intervention receiving Ticagrelor 60\u00a0mg vs. 90\u00a0mg"],"prefix":"10.1007","volume":"59","author":[{"given":"Raffaele","family":"Piccolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Laino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Pio","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Enrico","family":"Canonico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Avvedimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorenzo","family":"Simonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Paolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio Dal","family":"Piaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Charlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Cristiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi Di","family":"Serafino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Plinio","family":"Cirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Gargiulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Franzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Filippelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,16]]},"reference":[{"key":"3206_CR1","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1016\/j.jacc.2018.09.057","volume":"72","author":"D Capodanno","year":"2018","unstructured":"Capodanno D, Alfonso F, Levine GN et al (2018) ACC\/AHA versus ESC guidelines on dual antiplatelet therapy. J Am Coll Cardiol 72:2915\u20132931. https:\/\/doi.org\/10.1016\/j.jacc.2018.09.057","journal-title":"J Am Coll Cardiol"},{"key":"3206_CR2","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/S0140-6736(25)00055-8","volume":"405","author":"S Zaman","year":"2025","unstructured":"Zaman S, Wasfy JH, Kapil V et al (2025) The lancet commission on rethinking coronary artery disease: moving from ischaemia to atheroma. Lancet 405:1264\u20131312. https:\/\/doi.org\/10.1016\/S0140-6736(25)00055-8","journal-title":"Lancet"},{"key":"3206_CR3","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1080\/14740338.2017.1315101","volume":"16","author":"AS Nathan","year":"2017","unstructured":"Nathan AS, Sen S, Yeh RW (2017) The risk of bleeding with the use of antiplatelet agents for the treatment of cardiovascular disease. Expert Opin Drug Saf 16:561\u2013572. https:\/\/doi.org\/10.1080\/14740338.2017.1315101","journal-title":"Expert Opin Drug Saf"},{"key":"3206_CR4","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/eurheartj\/ehw525","volume":"38","author":"M Valgimigli","year":"2016","unstructured":"Valgimigli M, Costa F, Lokhnygina Y et al (2016) Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRACER) randomized trial. Eur Heart J 38:804\u2013810. https:\/\/doi.org\/10.1093\/eurheartj\/ehw525","journal-title":"Eur Heart J"},{"key":"3206_CR5","doi-asserted-by":"publisher","first-page":"550","DOI":"10.4244\/EIJ-D-20-01197","volume":"17","author":"R Piccolo","year":"2021","unstructured":"Piccolo R, Oliva A, Avvedimento M et al (2021) Mortality after bleeding versus myocardial infarction in coronary artery disease: a systematic review and meta-analysis. EuroIntervention 17:550\u2013560. https:\/\/doi.org\/10.4244\/EIJ-D-20-01197","journal-title":"EuroIntervention"},{"key":"3206_CR6","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/eurheartj\/ehaa824","volume":"42","author":"D Cao","year":"2021","unstructured":"Cao D, Chandiramani R, Chiarito M et al (2021) Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey. Eur Heart J 42:339\u2013351. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa824","journal-title":"Eur Heart J"},{"key":"3206_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41569-021-00598-1","volume":"19","author":"D Capodanno","year":"2022","unstructured":"Capodanno D, Bhatt DL, Gibson CM et al (2022) Bleeding avoidance strategies in percutaneous coronary intervention. Nat Rev Cardiol 19:117\u2013132. https:\/\/doi.org\/10.1038\/s41569-021-00598-1","journal-title":"Nat Rev Cardiol"},{"key":"3206_CR8","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/ehjcvp\/pvae054","volume":"10","author":"R Piccolo","year":"2024","unstructured":"Piccolo R, Simonetti F, Avvedimento M et al (2024) Ticagrelor 60 vs. 90 mg in elderly ACS patients undergoing PCI: a randomized, crossover trial. Eur Heart J 10:578\u2013587. https:\/\/doi.org\/10.1093\/ehjcvp\/pvae054","journal-title":"Eur Heart J"},{"key":"3206_CR9","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.jacc.2011.09.075","volume":"59","author":"TY Wang","year":"2012","unstructured":"Wang TY, Angiolillo DJ, Cushman M et al (2012) Platelet biology and response to antiplatelet therapy in women. J Am Coll Cardiol 59:891\u2013900. https:\/\/doi.org\/10.1016\/j.jacc.2011.09.075","journal-title":"J Am Coll Cardiol"},{"key":"3206_CR10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/eurheartj\/ehv758","volume":"38","author":"WT Wang","year":"2016","unstructured":"Wang WT, James SK, Wang TY (2016) A review of sex-specific benefits and risks of antithrombotic therapy in acute coronary syndrome. Eur Heart J 38:165\u2013171. https:\/\/doi.org\/10.1093\/eurheartj\/ehv758","journal-title":"Eur Heart J"},{"key":"3206_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvaf034","author":"M Galli","year":"2025","unstructured":"Galli M, Terracina S, Schiera E et al (2025) Sex-related variations in platelet reactivity in presence or absence of antiplatelet therapy. Eur Heart J. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaf034","journal-title":"Eur Heart J"},{"key":"3206_CR12","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s10557-021-07302-y","volume":"37","author":"R Piccolo","year":"2023","unstructured":"Piccolo R, Avvedimento M, Canonico ME et al (2023) Platelet inhibition with ticagrelor 60 mg versus 90 mg twice daily in elderly patients with acute coronary syndrome: rationale and design of the PLINY THE ELDER trial. Cardiovasc Drugs Ther 37:1031\u20131038. https:\/\/doi.org\/10.1007\/s10557-021-07302-y","journal-title":"Cardiovasc Drugs Ther"},{"key":"3206_CR13","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.120.046928","volume":"142","author":"G Gargiulo","year":"2020","unstructured":"Gargiulo G, Esposito G, Avvedimento M et al (2020) Cangrelor, tirofiban, and chewed or standard prasugrel regimens in patients with ST-segment\u2013elevation myocardial infarction. Circulation 142:441\u2013454. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.046928","journal-title":"Circulation"},{"key":"3206_CR14","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/253355a0","volume":"253","author":"M JOHNSON","year":"1975","unstructured":"JOHNSON M, RAMWELL RAMEYE (1975) Sex and age differences in human platelet aggregation. Nature 253:355\u2013357. https:\/\/doi.org\/10.1038\/253355a0","journal-title":"Nature"},{"key":"3206_CR15","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1001\/jama.295.12.1420","volume":"295","author":"DM Becker","year":"2006","unstructured":"Becker DM, Segal J, Vaidya D et al (2006) Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA 295:1420\u20131427. https:\/\/doi.org\/10.1001\/jama.295.12.1420","journal-title":"JAMA"},{"key":"3206_CR16","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s12471-011-0189-y","volume":"19","author":"NJ Breet","year":"2011","unstructured":"Breet NJ, Sluman MA, van Berkel MAJPJ et al (2011) Effect of gender difference on platelet reactivity. Neth Heart J 19:451\u2013457. https:\/\/doi.org\/10.1007\/s12471-011-0189-y","journal-title":"Neth Heart J"},{"key":"3206_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102406","volume":"8","author":"MV Chan","year":"2024","unstructured":"Chan MV, Chen M-H, Thibord F et al (2024) Factors that modulate platelet reactivity as measured by 5 assay platforms in 3429 individuals. Res Pract Thromb Haemost 8:102406. https:\/\/doi.org\/10.1016\/j.rpth.2024.102406","journal-title":"Res Pract Thromb Haemost"},{"key":"3206_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvaf034","author":"M Galli","year":"2025","unstructured":"Galli M, Terracina S, Schiera E et al (2025) Sex-related variations in platelet reactivity in presence or absence of antiplatelet therapy. Eur Heart J Cardiovasc Pharmacother Published Online First: 14 May. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaf034","journal-title":"Eur Heart J Cardiovasc Pharmacother Published Online First: 14 May"},{"issue":"9","key":"3206_CR19","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.amjcard.2007.12.038","volume":"101","author":"R Qayyum","year":"2008","unstructured":"Qayyum R, Becker DM, Yanek LR et al (2008) Platelet inhibition by aspirin 81 and 325 mg\/day in men versus women without clinically apparent cardiovascular disease. Am J Cardiol 101(9):1359\u20131363. https:\/\/doi.org\/10.1016\/j.amjcard.2007.12.038","journal-title":"Am J Cardiol"},{"key":"3206_CR20","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.amjcard.2009.04.027","volume":"104","author":"H Shen","year":"2009","unstructured":"Shen H, Herzog W, Drolet M et al (2009) Aspirin resistance in healthy drug-naive men versus women (from the heredity and phenotype intervention heart study). Am J Cardiol 104:606\u2013612. https:\/\/doi.org\/10.1016\/j.amjcard.2009.04.027","journal-title":"Am J Cardiol"},{"key":"3206_CR21","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014726","volume":"9","author":"KA Friede","year":"2020","unstructured":"Friede KA, Infeld MM, Tan RS et al (2020) Influence of sex on platelet reactivity in response to aspirin. J Am Heart Assoc 9:e014726. https:\/\/doi.org\/10.1161\/JAHA.119.014726","journal-title":"J Am Heart Assoc"},{"key":"3206_CR22","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.jacc.2015.12.062","volume":"67","author":"RF Storey","year":"2016","unstructured":"Storey RF, Angiolillo DJ, Bonaca MP et al (2016) Platelet inhibition with ticagrelor 60 mg versus 90 mg twice daily in the PEGASUS-TIMI 54 trial. J Am Coll Cardiol 67:1145\u20131154. https:\/\/doi.org\/10.1016\/j.jacc.2015.12.062","journal-title":"J Am Coll Cardiol"},{"key":"3206_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/ehjcvp\/pvz004","volume":"5","author":"J Kubica","year":"2019","unstructured":"Kubica J, Adamski P, Buszko K et al (2019) Platelet inhibition with standard vs. lower maintenance dose of Ticagrelor early after myocardial infarction (ELECTRA): a randomized, open-label, active-controlled pharmacodynamic and pharmacokinetic study. Eur Heart J 5:139\u2013148. https:\/\/doi.org\/10.1093\/ehjcvp\/pvz004","journal-title":"Eur Heart J"},{"key":"3206_CR24","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","volume":"372","author":"MP Bonaca","year":"2015","unstructured":"Bonaca MP, Bhatt DL, Cohen M et al (2015) Long-term use of Ticagrelor in patients with prior myocardial infarction. N Engl J Med 372:1791\u20131800. https:\/\/doi.org\/10.1056\/NEJMoa1500857","journal-title":"N Engl J Med"},{"key":"3206_CR25","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1093\/eurheartj\/ehad362","volume":"44","author":"D Capodanno","year":"2023","unstructured":"Capodanno D, Angiolillo DJ (2023) Personalised antiplatelet therapies for coronary artery disease: what the future holds. Eur Heart J 44:3059\u20133072. https:\/\/doi.org\/10.1093\/eurheartj\/ehad362","journal-title":"Eur Heart J"},{"key":"3206_CR26","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.thromres.2008.03.023","volume":"123","author":"HL Nielsen","year":"2008","unstructured":"Nielsen HL, Kristensen SD, Thygesen SS et al (2008) Aspirin response evaluated by the verifyNow\u2122 aspirin system and light transmission aggregometry. Thromb Res 123:267\u2013273. https:\/\/doi.org\/10.1016\/j.thromres.2008.03.023","journal-title":"Thromb Res"},{"key":"3206_CR27","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/j.1538-7836.2010.04160.x","volume":"9","author":"PCJ Armstrong","year":"2011","unstructured":"Armstrong PCJ, Leadbeater PD, Chan MV et al (2011) In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. J Thromb Haemost 9:552\u2013561. https:\/\/doi.org\/10.1111\/j.1538-7836.2010.04160.x","journal-title":"J Thromb Haemost"},{"key":"3206_CR28","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1111\/j.1538-7836.2011.04453.x","volume":"9","author":"NS Kirkby","year":"2011","unstructured":"Kirkby NS, Leadbeater PDM, Chan MV et al (2011) Antiplatelet effects of aspirin vary with level of P2Y12 receptor blockade supplied by either ticagrelor or prasugrel. J Thromb Haemost 9:2103\u20132105. https:\/\/doi.org\/10.1111\/j.1538-7836.2011.04453.x","journal-title":"J Thromb Haemost"},{"key":"3206_CR29","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1540-8183.2011.00670.x","volume":"24","author":"MA Gaglia","year":"2011","unstructured":"Gaglia MA, Torguson R, Pakala R et al (2011) Correlation between light transmission aggregometry, VerifyNow P2Y12, and VASP-P platelet reactivity assays following percutaneous coronary intervention. J Interv Cardiol 24:529\u2013534. https:\/\/doi.org\/10.1111\/j.1540-8183.2011.00670.x","journal-title":"J Interv Cardiol"},{"key":"3206_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/ehjcvp\/pvw026","volume":"3","author":"MJA Vries","year":"2017","unstructured":"Vries MJA, Bouman HJ, Olie RH et al (2017) Determinants of agreement between proposed therapeutic windows of platelet function tests in vulnerable patients. Eur Heart J Cardiovasc Pharmacother 3:11\u201317. https:\/\/doi.org\/10.1093\/ehjcvp\/pvw026","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"3206_CR31","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1080\/09537104.2020.1754378","volume":"32","author":"A-M Hulshof","year":"2021","unstructured":"Hulshof A-M, Vries M, Verhezen P et al (2021) The influence of prostaglandin E1 and use of inhibitor percentage on the correlation between the multiplate and VerifyNow in patients on dual antiplatelet therapy. Platelets 32:463\u2013468. https:\/\/doi.org\/10.1080\/09537104.2020.1754378","journal-title":"Platelets"},{"issue":"1","key":"3206_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11239-020-02170-z","volume":"51","author":"DA Gorog","year":"2021","unstructured":"Gorog DA, Becker RC (2021) Point-of-care platelet function tests: relevance to arterial thrombosis and opportunities for improvement. J Thromb Thrombolysis 51(1):1\u201311. https:\/\/doi.org\/10.1007\/s11239-020-02170-z","journal-title":"J Thromb Thrombolysis"},{"key":"3206_CR33","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1160\/TH07-09-0575","volume":"99","author":"JA Jakubowski","year":"2008","unstructured":"Jakubowski JA, Payne CD, Li YG et al (2008) The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following Prasugrel and clopidogrel administration. Thromb Haemost 99:409\u2013415. https:\/\/doi.org\/10.1160\/TH07-09-0575","journal-title":"Thromb Haemost"},{"key":"3206_CR34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/FJC.0b013e3181dd0ec2","volume":"56","author":"JA Jakubowski","year":"2010","unstructured":"Jakubowski JA, Li YG, Small DS et al (2010) A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with Prasugrel and clopidogrel: an integrated analysis. J Cardiovasc Pharmacol 56:29\u201337. https:\/\/doi.org\/10.1097\/FJC.0b013e3181dd0ec2","journal-title":"J Cardiovasc Pharmacol"},{"key":"3206_CR35","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1111\/jth.12376","volume":"11","author":"N Kakouros","year":"2013","unstructured":"Kakouros N, Kickler TS, Laws KM et al (2013) Hematocrit alters VerifyNow P2Y12 assay results independently of intrinsic platelet reactivity and clopidogrel responsiveness. J Thromb Haemost 11:1814\u20131822. https:\/\/doi.org\/10.1111\/jth.12376","journal-title":"J Thromb Haemost"},{"key":"3206_CR36","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1055\/s-0029-1220324","volume":"35","author":"M Cattaneo","year":"2009","unstructured":"Cattaneo M (2009) Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. Semin Thromb Hemost 35:158\u2013167. https:\/\/doi.org\/10.1055\/s-0029-1220324","journal-title":"Semin Thromb Hemost"},{"key":"3206_CR37","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1161\/CIRCULATIONAHA.118.034790","volume":"138","author":"RC Orme","year":"2018","unstructured":"Orme RC, Parker WAE, Thomas MR et al (2018) Study of two dose regimens of Ticagrelor compared with clopidogrel in patients undergoing percutaneous coronary intervention for stable coronary artery disease. Circulation 138:1290\u20131300. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034790","journal-title":"Circulation"},{"key":"3206_CR38","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s11239-021-02386-7","volume":"51","author":"DJ Angiolillo","year":"2021","unstructured":"Angiolillo DJ, Been L, Rubinstein M et al (2021) Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor. J Thromb Thrombolysis 51:741\u2013747. https:\/\/doi.org\/10.1007\/s11239-021-02386-7","journal-title":"J Thromb Thrombolysis"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03206-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-025-03206-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03206-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T13:41:42Z","timestamp":1780926102000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-025-03206-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,16]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["3206"],"URL":"https:\/\/doi.org\/10.1007\/s11239-025-03206-y","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,16]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide license to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to (i) publish, reproduce, distribute, display and store the Contribution, (ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and\/or, abstracts of the Contribution, (iii) create any other derivative work(s) based on the Contribution, (iv) to exploit all subsidiary rights in the Contribution, (v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, (vi) license any third party to do any or all of the above.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Copyright\/license for publication"}},{"value":"Not required.\u00a0","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"RP is the guarantor for this work and accepts full responsibility for the conduct of the study, had access to the data, and controlled the decision to publish. The corresponding author (RP) attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor information"}},{"value":"The manuscript\u2019s guarantor (RP) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned (and, if relevant, registered) have been explained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Transparency statement"}}]}}